← Back to Screener
Alaunos Therapeutics, Inc. Common Stock (TCRT)
Price$2.83
Favorite Metrics
Price vs S&P 500 (26W)-25.88%
Price vs S&P 500 (4W)-17.44%
Market Capitalization$7.09M
All Metrics
Book Value / Share (Quarterly)$0.92
P/TBV (Annual)0.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-88.04%
Cash Flow / Share (Quarterly)$-1.26
Price vs S&P 500 (YTD)-13.17%
Net Profit Margin (TTM)-39320.00%
EPS (TTM)$-2.21
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-2.21
EPS (Annual)$-2.14
ROI (Annual)-193.96%
Net Profit Margin (5Y Avg)-170837.58%
Cash / Share (Quarterly)$0.59
Revenue Growth QoQ (YoY)-25.00%
ROA (Last FY)-140.80%
Revenue Growth TTM (YoY)-44.44%
EBITD / Share (TTM)$-2.14
ROE (5Y Avg)-242.29%
Operating Margin (TTM)-39980.00%
Cash Flow / Share (Annual)$-1.26
P/B Ratio3.29x
P/B Ratio (Quarterly)3.35x
Net Income / Employee (Annual)$-4
EV / Revenue (TTM)1141.38x
Net Interest Coverage (TTM)-17.29x
ROA (TTM)-123.32%
EPS Incl Extra (Annual)$-2.14
Current Ratio (Annual)2.45x
Quick Ratio (Quarterly)1.71x
3-Month Avg Trading Volume0.03M
52-Week Price Return15.14%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.06
P/S Ratio (Annual)1418.39x
Asset Turnover (Annual)0.00x
52-Week High$6.20
Operating Margin (5Y Avg)-167729.21%
EPS Excl Extra (Annual)$-2.14
CapEx CAGR (5Y)-60.17%
Tangible BV CAGR (5Y)-3.96%
26-Week Price Return-21.89%
Quick Ratio (Annual)1.71x
13-Week Price Return1.40%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.45x
Enterprise Value$5.707
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-13.48%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-83520.00%
Cash / Share (Annual)$0.59
3-Month Return Std Dev65.88%
Net Income / Employee (TTM)$-4
ROE (Last FY)-193.96%
Net Interest Coverage (Annual)-9.09x
EPS Basic Excl Extra (Annual)$-2.14
Receivables Turnover (TTM)1.25x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.21
Receivables Turnover (Annual)1.25x
ROI (TTM)-172.65%
P/S Ratio (TTM)1418.39x
Pretax Margin (5Y Avg)-170837.58%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.16
Price vs S&P 500 (52W)-14.69%
Year-to-Date Return-10.53%
5-Day Price Return2.12%
EPS Normalized (Annual)$-2.14
ROA (5Y Avg)-175.40%
Net Profit Margin (Annual)-83520.00%
Month-to-Date Return1.05%
Cash Flow / Share (TTM)$-0.14
EBITD / Share (Annual)$-2.14
Operating Margin (Annual)-84500.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-228.39%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.21
P/TBV (Quarterly)1.15x
P/B Ratio (Annual)3.35x
Pretax Margin (TTM)-39320.00%
Book Value / Share (Annual)$0.92
Price vs S&P 500 (13W)0.72%
Beta-1.15x
Revenue / Share (TTM)$0.00
ROE (TTM)-172.65%
52-Week Low$1.67
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TCRTAlaunos Therapeutics, Inc. Common Stock | 1418.39x | -44.44% | — | — | $2.83 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Alaunos Therapeutics is a preclinical-stage biopharmaceutical company developing small-molecule oral therapies for obesity and metabolic disorders. Its lead program, ALN1001, aims to differentiate itself from GLP-1 receptor agonists by preserving lean muscle mass while treating obesity. The company is evaluating the compound's effects on lipid metabolism and gene expression to establish a competitive profile in the obesity treatment market.